LITS · Lite Strategy, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Covered Call Options notional outstanding | $7.9M | fiscal year ended June 30, 2026 filing | — |
| Digital assets | 650,716 | fiscal year ended June 30, 2026 filing | — |
| Digital assets receivable, net | 182,000 | fiscal year ended June 30, 2026 filing | — |
| Total digital assets (quantity) | 832,716 | fiscal year ended June 30, 2026 filing | — |
| average price per share repurchased | $1.11 | since December 2025 through July 17, 2026 | — |
| capital deployed for repurchases | $5.4M | since December 2025 through July 17, 2026 | — |
| LTC held | 819,070 | as of July 17, 2026 | — |
| percentage of outstanding shares repurchased | 13% | since December 2025 through July 17, 2026 | — |
| shares outstanding | 31,882,648 | as of July 17, 2026 | — |
| shares repurchased | 4.9M | since December 2025 through July 17, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LITS
this stock
Lite Strategy, Inc.
|
$36.18M | -9.8% | -100.0% | — | 0.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LITS | -1.7% | -8.5% | +3.5% | -9.9% | -9.9% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -0.5% | -7.9% | -4.6% | -10.7% | -22.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.